The advantage of dual PPARα/γ agonists is, that they, in addition to the insulin-sensitizing effects of PPARγ, improve lipid parameters and reduce cardiovascular complications associated with metabolic disorders through PPARα [16,47]. This evidence concerns the gene PPARA and metabolic disease.